Clinical Trial Market Research Reports & Industry Analysis
Clinical Trial Industry Research & Market Reports
-
Ocular Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape. Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular ... Read More
-
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... FXN or EC 1.16.3.1) pipeline Target constitutes close to 21 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report Frataxin Mitochondrial - Drugs In Development, ... Read More
-
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... recently published report 'Leucine Rich Repeat Serine Threonine Protein Kinase 2 - Drugs In Development, 2022'; Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 25 ... Read More
-
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Update Summary Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded ... Read More
-
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... - Drugs In Development, 2022, provides an overview of the Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline landscape. Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role ... Read More
-
Periodontitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Periodontitis (Mouth And Dental Disorders) pipeline landscape. Periodontitis is a gum infection that damages the soft tissue and destroys the bone that supports teeth. Signs and symptoms of periodontitis include swollen gums, ... Read More
-
Viral Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Viral Conjunctivitis (Ophthalmology) pipeline landscape. Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10-12 days from ... Read More
-
Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Leiomyosarcoma (Oncology) pipeline landscape. Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. Symptoms include a noticeable lump or swelling, pain, ... Read More
-
Synovial Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape. Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, ... Read More
-
Osteosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Osteosarcoma (Oncology) pipeline landscape. Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone ... Read More
-
Bronchopulmonary Dysplasia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Bronchopulmonary Dysplasia (Respiratory) pipeline landscape. Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation. Symptoms of BPD include ... Read More
-
Crohn's Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Crohn's Disease (Gastrointestinal) pipeline landscape. Crohn’s disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, ... Read More
-
Cell Division Protein FtsZ (ftsz) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... molecules. Out of which approximately 2 molecules are developed by companies and remaining by the universities/institutes. The latest report GMDHC22072TDB - Cell Division Protein FtsZ - Drugs In Development, 2022, outlays comprehensive information on the ... Read More
-
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Update Summary According to the recently published report 'Tyrosine Protein Kinase Mer - Drugs In Development, 2022'; Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) ... Read More
-
Fabry Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape. Fabry disease is an X-linked lysosomal disorder that results in abnormal deposits of globotriaosylceramide in blood vessel walls throughout the body. It is caused ... Read More
-
Thalassemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Thalassemia (Hematological Disorders) pipeline landscape. Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure ... Read More
-
African Trypanosomiasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the African Trypanosomiasis (Infectious Disease) pipeline landscape. African trypanosomiasis (also known as African sleeping sickness) is a parasitic infection caused by a species of parasite, Trypanosoma brucei, which is transmitted to ... Read More
-
Chronic Kidney Disease Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
... suffer from an irreversible and progressive loss in renal function over many months or years, ultimately resulting in end-stage renal disease and the requirement for renal replacement therapy. CKD manifests when both kidneys are damaged ... Read More
-
Optic Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Optic Neuropathy (Ophthalmology) pipeline landscape. Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, ... Read More
-
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... 'Exportin 1 - Drugs In Development, 2022'; Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. Exportin ... Read More
-
Severe Acute Respiratory Syndrome (SARS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... (SARS) - Drugs In Development, 2022, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape. Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus ... Read More
-
Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape. Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). ... Read More
-
Influenza A Virus, H3N2 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... H3N2 Subtype Infections - Drugs In Development, 2022, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape. H3N2 infections are caused by variant H3N2 virus which is an influenza ... Read More
-
Diabetic Nephropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape. Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high ... Read More
-
Dyslipidemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape. Dyslipidemia is defined as elevation of the total cholesterol, the bad low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the good high-density lipoprotein ... Read More
Research Assistance
